We are live on ! Find out more
RCM

Revelation Capital Management Portfolio holdings

AUM $67.4M
This Fund
S&P 500
This Quarter Est. Return
-8.86%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$104M
AUM Growth
Cap. Flow
+$125M
Cap. Flow %
120.58%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OMIC
1
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$60.3M 58.21%
+173,998
New +$67.4M
ME
2
DELISTED
23andMe Holding Co
ME
$31.1M 29.99%
+233,387
New +$43.1M
NPCE icon
3
Neuropace
NPCE
$522M
$6.72M 6.48%
+666,540
New +$8.66M
SLGC
4
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.32M 4.16%
+370,839
New +$4.44M
NTRA icon
5
Natera
NTRA
$36.1B
$739K 0.71%
+7,923
New +$822K
CVRX icon
6
CVRx
CVRX
$131M
$467K 0.45%
+38,182
New +$554K

Similar funds

Revelation Capital Management's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for Revelation Capital Management, which disclosed 6 positions worth $104M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Singular Genomics Systems, Inc. Common Stock: 173,998 shares worth $60.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Revelation Capital Management's largest Q4 2021 buy was Singular Genomics Systems, Inc. Common Stock: 173,998 shares worth $60.3M.
  • Revelation Capital Management's ten largest holdings make up 100% of its $104M portfolio in Q4 2021.
  • Revelation Capital Management disclosed 6 positions in Q4 2021, its first 13F filing on record.

Based on Revelation Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.